Funding accelerates advancement of first-in-class non-invasive neuromodulation platform to transform the arc of stroke care in ICUs

资金加速推进首创的非侵入式神经调控平台，以改变重症监护室中风治疗的轨迹

ST. LOUIS

圣路易斯

,

，

July 28, 2026

2026年7月28日

/PRNewswire/ --

/美通社/ --

Aurenar

奥雷纳尔

, developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in intensive care unit (ICU) patients, today announced the close of an oversubscribed $5.7 million seed financing round, co-led by the

，一家开发非侵入性、一次性神经调节平台以减少重症监护室（ICU）患者危及生命的并发症的公司，今日宣布完成一轮超额认购的570万美元种子轮融资，由

Go Red for Women Venture Fund™

女性红心创业基金™

, part of American Heart Association Ventures™ — the American Heart Association's venture capital arm — and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. Proceeds from the investment round will fund continued advancement toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S.

作为美国心脏协会风投（American Heart Association Ventures™，即美国心脏协会的风险投资部门）和Solas BioVentures的一部分，并得到BJC Health和Kaleida Capital的额外参与。本轮融资所得资金将用于推动关键性试验的持续进展，包括最终的设备开发、验证与确认（V&V）测试，以及向美国监管机构提交的注册申请。

Food and Drug Administration (FDA)..

美国食品药品监督管理局（FDA）

Aurenar's V-Link™ platform, which recently received

Aurenar 的 V-Link™ 平台，该平台最近获得了

breakthrough device designation

突破性设备认定

from the FDA, delivers transauricular vagus nerve stimulation (taVNS) to modulate the body's inflammatory response to such conditions as subarachnoid hemorrhage (SAH). SAH alone accounts for roughly 7% of all strokes worldwide, leaving approximately 40% of survivors with permanent disability. Initially developed to respond to stroke and broader neurocritical-care challenges, V-Link has the potential to expand into additional high-impact indications in critically ill patients..

V-Link 已获得美国食品药品监督管理局（FDA）批准，通过经耳迷走神经刺激（taVNS）来调节机体对蛛网膜下腔出血（SAH）等疾病的炎症反应。仅 SAH 就约占全球所有卒中病例的 7%，且约 40% 的幸存者会遗留永久性残疾。V-Link 最初旨在应对卒中及更广泛的神经重症监护挑战，未来有望拓展至危重患者中其他具有高临床影响的适应症。

Inflammation is a central driver of the secondary injury that worsens outcomes in stroke, subarachnoid hemorrhage, and other critical illnesses. Modulating this cascade non-invasively in the ICU addresses a significant unmet need — and a meaningful opportunity to change recovery trajectories for many patients experiencing the most acute, high-risk conditions that also increase hospital costs..

炎症是加剧卒中、蛛网膜下腔出血及其他危重疾病不良预后的继发性损伤的核心驱动因素。在重症监护室（ICU）中通过非侵入性方式调节这一炎症级联反应，能够满足一个尚未被满足的重大临床需求，并为改善许多处于最急性、高风险状态患者的康复轨迹提供重要契机，同时也有助于降低住院成本。

The company was founded based on research from Dr. Eric Leuthardt, Dr. Anna Huguenard, and colleagues at Washington University School of Medicine in St. Louis. The

该公司基于圣路易斯华盛顿大学医学院的埃里克·洛伊特哈特博士、安娜·于格纳尔博士及其同事的研究而成立。

randomized SAH trial

随机化蛛网膜下腔出血试验

they conducted demonstrated that taVNS reduced moderate-to-severe vasospasm by more than 40%, lowered pro-inflammatory cytokines, and improved functional outcomes. A

他们开展的研究表明，taVNS 使中重度血管痉挛减少了 40% 以上，降低了促炎细胞因子水平，并改善了功能结局。A

companion analysis

伴侣分析

also showed a 20% drop in 30-day modifiable hospitalization costs directly linked to the method. A separate large-vessel occlusion (LVO)

还显示，与该方案直接相关的30天内可调整的住院费用下降了20%。另一项大血管闭塞（LVO）

ischemic stroke trial

缺血性卒中试验

showed consistent anti-inflammatory effects and a clean safety profile.

显示出一致的抗炎作用，且安全性良好。

V-Link's simple, wireless design makes it easier for neuro-intensive care physicians and ICU nursing staff to use the device without extensive training and supports faster onboarding and clinical adoption.

V-Link 的简易无线设计使神经重症监护医师和 ICU 护理人员无需接受大量培训即可轻松使用该设备，并有助于加快人员上岗和临床推广。

'We are excited to support Aurenar because stroke is a major cause of mortality and long-term disability in women, who face a disproportionately higher prevalence of subarachnoid hemorrhage. Their V-Link product promises to offer a pathway to improve recovery for all patients and especially for women who often experience higher rates of post-stroke complications,' said Tracy Warren, Sr.

“我们很高兴支持Aurenar，因为中风是女性死亡和长期残疾的主要原因，而女性面临蛛网膜下腔出血的患病率不成比例地更高。他们的V-Link产品有望为所有患者提供一条改善康复的途径，尤其是对于经常经历更高中风后并发症发生率的女性。”高级副总裁Tracy Warren表示。

Managing Director, Go Red for Women Venture Fund, part of the American Heart Association Ventures family of funds. 'The potential for use with other conditions that trigger the body's inflammatory response, which also disproportionately affect women, makes V-Link the kind of scalable innovation our fund was created to accelerate.'.

美国心脏协会风险投资基金旗下“Go Red for Women”风险基金的管理董事表示：“V-Link有望应用于其他引发机体炎症反应且对女性影响尤为严重的疾病，这正是我们基金旨在加速推进的可规模化创新类型。”

'This seed close marks a pivotal moment for Aurenar,' said Dr. Leuthardt, Founder and Chief Executive Officer of Aurenar and a professor of neurosurgery at WashU Medicine. 'With the support of the Go Red for Women Venture Fund, Solas BioVentures, and our broader investor group, we are positioned to advance from early-stage neurotechnology to a pivotal-trial-ready company.

“本轮种子轮融资的完成标志着Aurenar发展史上的一个关键里程碑，”Aurenar创始人兼首席执行官、华盛顿大学医学院神经外科教授Leuthardt博士表示，“在‘Go Red for Women’风险投资基金、Solas BioVentures以及我们更广泛投资者群体的支持下，我们已做好准备，从早期阶段的神经技术公司迈向具备开展关键性临床试验条件的企业。”

Every dollar of this round is committed to milestones that help us improve outcomes for patients in the most critical moments of their care.'.

本轮融资的每一美元都将用于实现那些有助于我们在患者护理最关键时刻改善其治疗结果的里程碑目标。

'At WashU, we are reinforcing pathways that convert bold scientific ideas into real-world solutions,' said Doug Frantz, PhD, Vice Chancellor for Innovation and Commercialization, Washington University. 'This neuromodulation platform is yet another example of the strength of WashU's innovation ecosystem, and Dr.

“在华盛顿大学，我们正在加强将大胆的科学构想转化为现实世界解决方案的途径，”华盛顿大学负责创新与商业化的副校长沙 Doug Frantz 博士表示。“这一神经调控平台是华盛顿大学创新生态系统实力的又一例证，而 Dr.”

Leuthardt's progress with Aurenar is bringing us closer to delivering meaningful advances to some of our most critically ill patients.'.

“Leuthardt 在 Aurenar 项目上的进展，正使我们能够为一些病情最为危重的患者带来具有实质意义的突破性治疗。”

About Aurenar

关于奥雷纳尔

Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company's transauricular vagus nerve stimulation (taVNS) device targets the body's inflammatory response to improve outcomes, lower total cost of care, and transform critical care management.

Aurenar 是一家正在开发非侵入性、一次性神经调节平台的公司，旨在降低重症监护室（ICU）患者危及生命的并发症风险。该公司的经耳迷走神经刺激（taVNS）设备针对身体的炎症反应，以改善患者预后、降低总体医疗成本，并变革重症监护管理。

Beginning with the impacts of stroke, Aurenar's platform is positioned to expand to address multiple high-acuity indications. Aurenar is headquartered in St. Louis, Missouri. Learn more at .

从卒中影响入手，Aurenar的平台有望扩展至多种高急重症适应症。Aurenar总部位于密苏里州圣路易斯。了解更多请访问。

www.aurenar.com

www.aurenar.com

.

。

About Go Red Fund and American Heart Association Ventures

关于 Go Red Fund 和美国心脏协会风险投资公司

The Go Red for Women Venture Fund™ invests in market-driven solutions across a spectrum of heart health, brain health and related conditions to improve health for women. The Fund invests in early-stage companies whose products and services improve access, diagnosis and treatment for women. Through focused investment that translates science into action, the Go Red Fund is sparking real-world change and making a measurable difference in women's lives..

“Go Red for Women 风险基金™”投资于涵盖心脏健康、大脑健康及相关状况的一系列市场驱动型解决方案，以改善女性健康。该基金投资于那些能够通过产品和服务改善女性在医疗可及性、诊断和治疗方面状况的早期阶段公司。通过将科学转化为行动的专注投资，Go Red 基金正在引发现实世界的变革，并为女性的生活带来可衡量的积极影响。

The

这

Go Red Venture Fund

Go Red 风险投资基金

is part of

是……的一部分

American Heart Association Ventures

美国心脏协会风险投资公司

, the venture capital platform of the American Heart Association.

，美国心脏协会的风险投资平台。

About Solas BioVentures

关于 Solas BioVentures

Solas BioVentures is a venture capital firm investing in early- and development-stage biopharmaceutical, medical device, and digital health companies. Founded by physicians, scientists, and operators, the firm pairs deep clinical expertise and a patient-centric approach to funding technologies advancing the standard of care.

Solas BioVentures 是一家风险投资公司，专注于投资处于早期和开发阶段的生物制药、医疗器械以及数字健康领域的企业。该公司由医生、科学家和行业运营专家共同创立，将深厚的临床专业知识与以患者为中心的理念相结合，致力于资助那些能够提升医疗护理标准的技术创新。

Solas is headquartered in Chattanooga, Tennessee, with a presence in Research Triangle Park, North Carolina. Learn more at .

Solas 总部位于田纳西州查塔努加，并在北卡罗来纳州研究三角园设有分支机构。了解更多详情，请访问 。

www.solasbio.com

www.solasbio.com

.

。

Solas BioVentures Management, LLC is an SEC-registered investment adviser. Registration does not imply a certain level of skill or training. For informational purposes only. Past performance is not indicative of future results. Investing involves risk, including the possibility of loss of principal.

Solas BioVentures Management, LLC 是一家在美国证券交易委员会（SEC）注册的投资顾问。注册并不意味着具备特定水平的技能或培训。本文仅提供信息参考。过往业绩并不预示未来表现。投资涉及风险，包括本金损失的可能性。

Learn more at .

了解更多，请访问。

https://adviserinfo.sec.gov/firm/summary/322344

https://adviserinfo.sec.gov/firm/summary/322344

.

。

SOURCE Aurenar

来源 Aurenar

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示